{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:23:56Z","timestamp":1774952636112,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.urolonc.2013.08.001","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T15:04:53Z","timestamp":1399647893000},"page":"537-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Calcium channel blockers and prostate cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"Kevin R.","family":"Loughlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.urolonc.2013.08.001_bib1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/sj.cdd.4402162","article-title":"Ion channels in death and differentiation of prostate cancer cells","volume":"14","author":"Prevarskoya","year":"2007","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.urolonc.2013.08.001_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002800000262","article-title":"Fendiline, anti-fungal drug increases intracellular Ca2+ in PC3 human prostate cancer cells","volume":"48","author":"Jan","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2013.08.001_bib3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0895-7061(98)00120-4","article-title":"Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist","author":"Sharifi","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.urolonc.2013.08.001_bib4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00125-001-0765-6","article-title":"Long acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodeling in a Type II diabetic rat model","volume":"45","author":"Jesmin","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.urolonc.2013.08.001_bib5","first-page":"611","article-title":"Heart rate and prostate cancer mortality: results of a prospective analysis","volume":"4","author":"Gann","year":"1995","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2013.08.001_bib6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S1047-2797(01)00246-0","article-title":"Hypertension heart rate, use of antihypertensives and incident prostate cancer","volume":"11","author":"Fitzpatrick","year":"2001","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.urolonc.2013.08.001_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2013.08.001_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-03-0093","article-title":"Inverse association between prostate cancer and the use of calcium channel blockers","volume":"13","author":"Debes","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2013.08.001_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0090-4295(00)00940-7","article-title":"Agents, biomarkers and cohorts for chemopreventative agent development in prostate cancer","volume":"57","author":"Kelloff","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.08.001_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pros.22632","article-title":"The association between calcium channel blocker use and prostate cancer outcome","volume":"73","author":"Poch","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2013.08.001_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","article-title":"Association between captopril, other antihypertensive drugs and risk of prostate cancer","volume":"58","author":"Ronquist","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2013.08.001_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.111.188151","article-title":"Diltiazen enhances the apoptotic effect of proteasome inhibitors to induce prostate cancer cell death","volume":"341","author":"Kaddour-Djebbar","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.urolonc.2013.08.001_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2164\/jandrol.106.000554","article-title":"Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells","volume":"5","author":"Sun","year":"2006","journal-title":"J Androl"},{"key":"10.1016\/j.urolonc.2013.08.001_bib14","doi-asserted-by":"crossref","unstructured":"Graham SM, Holzbeierstein JM, Thrasher JBLi B. Calcium channel blocker modulates androgen receptor\u2013mediated gene expression and induces cytotoxicity in prostate cancer cells. Abstract 227 American Urological Association Meeting, Atlanta, GA 2012","DOI":"10.1016\/j.juro.2012.02.281"},{"key":"10.1016\/j.urolonc.2013.08.001_bib15","doi-asserted-by":"crossref","unstructured":"Chen R, Zeng X, Zhang R. et al. Cav1.3 channel \u03b11D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol 2014;32:524\u201336","DOI":"10.1016\/j.urolonc.2013.05.011"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913003116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913003116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:02:36Z","timestamp":1761040956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143913003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1078143913003116"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.08.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium channel blockers and prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}